These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31779181)

  • 1. Synthesis and In Vitro Evaluation of Novel Liver X Receptor Agonists Based on Naphthoquinone Derivatives.
    Nishioka T; Endo-Umeda K; Ito Y; Shimoda A; Takeuchi A; Tode C; Hirota Y; Osakabe N; Makishima M; Suhara Y
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists.
    Nomura S; Endo-Umeda K; Makishima M; Hashimoto Y; Ishikawa M
    ChemMedChem; 2016 Oct; 11(20):2347-2360. PubMed ID: 27690261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.
    DiBlasio-Smith EA; Arai M; Quinet EM; Evans MJ; Kornaga T; Basso MD; Chen L; Feingold I; Halpern AR; Liu QY; Nambi P; Savio D; Wang S; Mounts WM; Isler JA; Slager AM; Burczynski ME; Dorner AJ; LaVallie ER
    J Transl Med; 2008 Oct; 6():59. PubMed ID: 18925943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches.
    Chen M; Yang F; Kang J; Gan H; Yang X; Lai X; Gao Y
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29867043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, structure activity relationships and X-Ray co-crystallography of non-steroidal LXR agonists.
    Bennett DJ; Carswell EL; Cooke AJ; Edwards AS; Nimz O
    Curr Med Chem; 2008; 15(2):195-209. PubMed ID: 18220775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.
    Aoyama A; Endo-Umeda K; Kishida K; Ohgane K; Noguchi-Yachide T; Aoyama H; Ishikawa M; Miyachi H; Makishima M; Hashimoto Y
    J Med Chem; 2012 Sep; 55(17):7360-77. PubMed ID: 22873709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
    Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
    Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and structure-activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists.
    Namba N; Noguchi-Yachide T; Matsumoto Y; Hashimoto Y; Fujii S
    Bioorg Med Chem; 2022 Jul; 66():116792. PubMed ID: 35576658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
    Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
    Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity.
    Karaboga H; Huang W; Srivastava S; Widmann S; Addanki S; Gamage KT; Mazhar Z; Ebalunode JO; Briggs JM; Gustafsson JÅ; Filgueira CS; Gilbertson SR; Lin CY
    ACS Chem Biol; 2020 Nov; 15(11):2916-2928. PubMed ID: 33074669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical and functional interactions between nuclear receptor LXRα and the forkhead box transcription factor FOXA2 regulate the response of the human lipoprotein lipase gene to oxysterols in hepatic cells.
    Kanaki M; Tiniakou I; Thymiakou E; Kardassis D
    Biochim Biophys Acta Gene Regul Mech; 2017 Aug; 1860(8):848-860. PubMed ID: 28576574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structurally Selective Mechanism of Liver X Receptor Ligand:
    Ding P; Chen Z; Chen H; Zhang Z; Liu Z; Yan X; Zhou H; Gu Q; Li C; Xu J
    J Chem Inf Model; 2019 Jul; 59(7):3277-3290. PubMed ID: 31192592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new LXRβ agonists as glioblastoma inhibitors.
    Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J
    Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold.
    Goher SS; Griffett K; Hegazy L; Elagawany M; Arief MMH; Avdagic A; Banerjee S; Burris TP; Elgendy B
    Bioorg Med Chem Lett; 2019 Feb; 29(3):449-453. PubMed ID: 30587446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Dehydrocholesterol metabolites produced by sterol 27-hydroxylase (CYP27A1) modulate liver X receptor activity.
    Endo-Umeda K; Yasuda K; Sugita K; Honda A; Ohta M; Ishikawa M; Hashimoto Y; Sakaki T; Makishima M
    J Steroid Biochem Mol Biol; 2014 Mar; 140():7-16. PubMed ID: 24269243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and activity evaluation of a series of cholanamides as modulators of the liver X receptors.
    Martínez MD; Ghini AA; Dansey MV; Veleiro AS; Pecci A; Alvarez LD; Burton G
    Bioorg Med Chem; 2018 Mar; 26(5):1092-1101. PubMed ID: 29428525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect.
    Tamura S; Okada M; Kato S; Shinoda Y; Shioda N; Fukunaga K; Ui-Tei K; Ueda M
    Sci Rep; 2018 Feb; 8(1):2305. PubMed ID: 29396543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissection of the insulin-sensitizing effect of liver X receptor ligands.
    Commerford SR; Vargas L; Dorfman SE; Mitro N; Rocheford EC; Mak PA; Li X; Kennedy P; Mullarkey TL; Saez E
    Mol Endocrinol; 2007 Dec; 21(12):3002-12. PubMed ID: 17717069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
    Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
    J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.
    Molteni V; Li X; Nabakka J; Liang F; Wityak J; Koder A; Vargas L; Romeo R; Mitro N; Mak PA; Seidel HM; Haslam JA; Chow D; Tuntland T; Spalding TA; Brock A; Bradley M; Castrillo A; Tontonoz P; Saez E
    J Med Chem; 2007 Aug; 50(17):4255-9. PubMed ID: 17665897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.